CR20170392A - Compuestos bicíclicos de sulfonamida cetona - Google Patents
Compuestos bicíclicos de sulfonamida cetonaInfo
- Publication number
- CR20170392A CR20170392A CR20170392A CR20170392A CR20170392A CR 20170392 A CR20170392 A CR 20170392A CR 20170392 A CR20170392 A CR 20170392A CR 20170392 A CR20170392 A CR 20170392A CR 20170392 A CR20170392 A CR 20170392A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bicyclic compounds
- sulfonamide
- ketone
- sulfonamide ketone
- atropisomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona compuestos de la Fórmula (I), en donde: como se define en la especificación, un enantiómero, diaestereómero, atropisómero del mismo, o una mezcla de los mismos, o sales farmacéuticamente aceptables de los mismos, que son inhibidores de los canales de sodio regulados por voltaje, en particular Nav 1.7
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127206P | 2015-03-02 | 2015-03-02 | |
| PCT/US2016/020403 WO2016141035A1 (en) | 2015-03-02 | 2016-03-02 | Bicyclic ketone sulfonamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170392A true CR20170392A (es) | 2018-02-20 |
Family
ID=55543087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170392A CR20170392A (es) | 2015-03-02 | 2016-03-02 | Compuestos bicíclicos de sulfonamida cetona |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10472356B2 (es) |
| EP (1) | EP3265465B1 (es) |
| JP (1) | JP6742331B2 (es) |
| KR (1) | KR102649836B1 (es) |
| CN (1) | CN107531705B (es) |
| AR (1) | AR103833A1 (es) |
| AU (1) | AU2016226340B2 (es) |
| BR (1) | BR112017018755B1 (es) |
| CA (1) | CA2978569C (es) |
| CL (1) | CL2017002153A1 (es) |
| CO (1) | CO2017009614A2 (es) |
| CR (1) | CR20170392A (es) |
| EA (1) | EA032928B1 (es) |
| ES (1) | ES2728759T3 (es) |
| HK (1) | HK1248687B (es) |
| IL (1) | IL254161B (es) |
| JO (1) | JO3595B1 (es) |
| MX (1) | MX2017011042A (es) |
| MY (1) | MY188700A (es) |
| NZ (1) | NZ734888A (es) |
| PE (1) | PE20180030A1 (es) |
| PH (1) | PH12017501570A1 (es) |
| SG (1) | SG11201707000UA (es) |
| TN (1) | TN2017000376A1 (es) |
| TW (1) | TWI700282B (es) |
| UY (1) | UY36573A (es) |
| WO (1) | WO2016141035A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| CN107991409B (zh) * | 2017-11-28 | 2020-04-24 | 中国医学科学院肿瘤医院 | 采用高效合相色谱同时测定血浆中12种磺胺类药物的方法 |
| CN111936494A (zh) * | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| WO2020199683A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海海雁医药科技有限公司 | 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| US11319960B2 (en) * | 2020-09-03 | 2022-05-03 | Shenzhen Lanhe Technologies Co., Ltd. | Portable temperature regulation device |
| US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| WO2022256708A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CA3221939A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4620007A (en) * | 1980-09-03 | 1986-10-28 | Bayer Aktiengesellschaft | 6-fluoro-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid |
| WO2005014558A1 (en) * | 2003-08-05 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
| DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| WO2006106423A2 (en) * | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2011103715A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| KR20140095067A (ko) * | 2011-10-28 | 2014-07-31 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서의 선택적 활성을 갖는 벤족사졸리논 화합물 |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9212182B2 (en) * | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-03-02 CA CA2978569A patent/CA2978569C/en active Active
- 2016-03-02 CR CR20170392A patent/CR20170392A/es unknown
- 2016-03-02 CN CN201680024836.2A patent/CN107531705B/zh active Active
- 2016-03-02 TN TNP/2017/000376A patent/TN2017000376A1/en unknown
- 2016-03-02 JP JP2017546195A patent/JP6742331B2/ja active Active
- 2016-03-02 SG SG11201707000UA patent/SG11201707000UA/en unknown
- 2016-03-02 MY MYPI2017001273A patent/MY188700A/en unknown
- 2016-03-02 TW TW105106422A patent/TWI700282B/zh active
- 2016-03-02 BR BR112017018755-8A patent/BR112017018755B1/pt active IP Right Grant
- 2016-03-02 WO PCT/US2016/020403 patent/WO2016141035A1/en active Application Filing
- 2016-03-02 ES ES16710566T patent/ES2728759T3/es active Active
- 2016-03-02 AR ARP160100551A patent/AR103833A1/es unknown
- 2016-03-02 JO JOP/2016/0032A patent/JO3595B1/ar active
- 2016-03-02 EP EP16710566.7A patent/EP3265465B1/en active Active
- 2016-03-02 UY UY0001036573A patent/UY36573A/es unknown
- 2016-03-02 MX MX2017011042A patent/MX2017011042A/es active IP Right Grant
- 2016-03-02 PE PE2017001464A patent/PE20180030A1/es unknown
- 2016-03-02 US US15/554,801 patent/US10472356B2/en active Active
- 2016-03-02 EA EA201791941A patent/EA032928B1/ru not_active IP Right Cessation
- 2016-03-02 AU AU2016226340A patent/AU2016226340B2/en active Active
- 2016-03-02 NZ NZ734888A patent/NZ734888A/en unknown
- 2016-03-02 KR KR1020177027941A patent/KR102649836B1/ko active IP Right Grant
-
2017
- 2017-08-24 CL CL2017002153A patent/CL2017002153A1/es unknown
- 2017-08-27 IL IL254161A patent/IL254161B/en active IP Right Grant
- 2017-08-31 PH PH12017501570A patent/PH12017501570A1/en unknown
- 2017-09-22 CO CONC2017/0009614A patent/CO2017009614A2/es unknown
-
2018
- 2018-06-26 HK HK18108233.0A patent/HK1248687B/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20170392A (es) | Compuestos bicíclicos de sulfonamida cetona | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| CL2018003474A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CL2017000820A1 (es) | Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos | |
| GT201600085A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| SV2016005137A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| UY36122A (es) | ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1? | |
| CY1122024T1 (el) | Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch | |
| CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| CO2017005959A2 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| UY36716A (es) | Moduladores de receptores nucleares | |
| CL2015002837A1 (es) | Compuestos de piridinilpirazoloquinolina. | |
| UY36654A (es) | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen | |
| CL2018001067A1 (es) | Compuesto piranodipiridínico. | |
| EA201892235A1 (ru) | Гранулированная композиция для перорального применения | |
| CO2017009989A2 (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda | |
| CR20160428A (es) | Pizazinas moduladoras de gpr6 | |
| CL2016001745A1 (es) | Ácido (s)-3'-metil-abscísico y ésteres del mismo | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека |